<i>Helicobacter pylori</i> infection: How does age influence the inflammatory pattern?

Araújo, Glauber Rocha Lima; Marques, Hanna Santos; Santos, Maria Luísa Cordeiro; Silva, Filipe Antônio França da; Brito, Breno Bittencourt de; Santos, Gabriel Lima Correa; Melo, Fabrício Freire de

doi:10.3748/wjg.v28.i4.402

Cited by 21 publications

(14 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 50% of the global population is infected by Helicobacter pylori, 1 that causes various diseases including peptic ulcer disease and gastric cancer. [2][3][4][5][6] Recent studies have demonstrated that H. pylori eradication therapy has a beneficial effect on reducing the risk of gastric cancer development. [7][8][9] Active eradication of H. pylori infection has been attempted in East Asian countries, 10 where H. pylori and gastric cancer are prevalent.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study

Jung

Kim

et al. 2022

Gut and Liver

View full text Add to dashboard Cite

Background/Aims: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, realworld clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of tegoprazan-and rabeprazole-based triple therapy. Methods:We retrospectively reviewed data from patients who received first-line treatment for H. pylori infection using tegoprazan-or rabeprazole-based triple therapy for 2 weeks (50 mg tegoprazan or 20 mg rabeprazole+1,000 mg amoxicillin+500 mg clarithromycin twice daily). The primary endpoint was the eradication rate as determined by intention-to-treat analysis.Results: Of the 677 patients included in our study, 344 and 333 received tegoprazan-based and rabeprazole-based triple therapy, respectively. The eradication rate from intention-to-treat analysis was 76.7% (95% confidence interval [CI], 72.1% to 81.0%) for tegoprazan-based triple therapy and 75.4% (95% CI, 70.5% to 79.8%) for rabeprazole-based triple therapy. There was no significant difference in the eradication rates between the two groups (p>0.999). Per-protocol analysis also revealed no significant difference between the eradication rates of the two groups (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [79.0% to 87.4%], p>0.999). Furthermore, there was no significant difference in adverse event rates between the two groups (tegoprazan, 27.6%; rabeprazole, 25.8%; p=0.604). Conclusions:The eradication rate of tegoprazan-based triple therapy was similar to that of rabeprazole-based triple therapy. Further studies on the dose-escalation effect of tegoprazan for H. pylori eradication and the efficacy of tegoprazan in regimens other than conventional triple therapy are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study

Jung

Kim

et al. 2022

Gut and Liver

View full text Add to dashboard Cite

show abstract

“…On the other hand, in adults, there is a predominant Th1 response, with higher mucosal levels of IFN-γ and IL12p70 [ 75 ]. Adults also have an increased Th17 response, with higher levels of IL-17A and IL-23 and lower concentrations of TGF-β1, with a cytokine profile more associated with epithelial damage [ 76 ]. Another mechanism involved in this crosstalk involves antimicrobial peptides such as defensins, molecules known to be active against bacteria, viruses, fungi, and protozoa, which are increased in H. pylori -induced gastritis [ 77 ].…”

Section: The Effect Of H Pylori On Gastric Microbiotamentioning

confidence: 99%

The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota

et al. 2023

View full text Add to dashboard Cite

Helicobacter pylori is a Gram-negative bacterium that is able to colonize the human stomach, whose high prevalence has a major impact on human health, due to its association with several gastric and extra-gastric disorders, including gastric cancer. The gastric microenvironment is deeply affected by H. pylori colonization, with consequent effects on the gastrointestinal microbiota, exerted via the regulation of various factors, including gastric acidity, host immune responses, antimicrobial peptides, and virulence factors. The eradication therapy required to treat H. pylori infection can also have detrimental consequences for the gut microbiota, leading to a decreased alpha diversity. Notably, therapy regimens integrated with probiotics have been shown to reduce the negative effects of antibiotic therapy on the gut microbiota. These eradication therapies combined with probiotics have also higher rates of eradication, when compared to standard treatments, and are associated with reduced side effects, improving the patient’s compliance. In light of the deep impact of gut microbiota alterations on human health, the present article aims to provide an overview of the complex interaction between H. pylori and the gastrointestinal microbiota, focusing also on the consequences of eradication therapies and the effects of probiotic supplementation.

show abstract

“…These responses in children focus on Treg cells with subsequent higher IL-10 and transforming growth factor (TGFβ) production. 32,33 In conclusion, additional studies on children are needed to obtain a more comprehensive insight into the effect of probiotics on H. pylori infection.…”

Section: Food and Function Papermentioning

confidence: 99%